



PROVIDING ANSWERS FOR CANCER PATIENTS

**Press release**

**7 December, 2021**

## **Curasight A/S presents at HC Andersen Capital & Nordea Markets Virtual Growth Days seminar - 9 December 2021**

**Curasight A/S CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company and its future plans at HC Andersen Capital & Nordea Markets Virtual Growth Days seminar.**

**The presentation will be webcasted live 09:00 – 09:15 (CET), Thursday 9 December 2021.**

**For more information and registration– please [click here](#)**

**For more information regarding Curasight, please contact:**

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: [uk@curasight.com](mailto:uk@curasight.com)

[www.curasight.com](http://www.curasight.com)

---

**Curasight** is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.